Heron Therapeutics
HRTX
104 hedge funds and large institutions have $964M invested in Heron Therapeutics in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 47 increasing their positions, 25 reducing their positions, and 11 closing their positions.
2,020% more call options, than puts
Call options by funds: $23.5M | Put options by funds: $1.11M
88% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 25
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
4% more funds holding
Funds holding: 100 → 104 (+4)
4.11% less ownership
Funds ownership: 133.75% → 129.64% (-4.1%)
10% less capital invested
Capital invested by funds: $1.07B → $964M (-$111M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$81.7M |
| 2 |
Citigroup
New York
|
+$15M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.26M |
| 4 |
TCP
Tourbillon Capital Partners
New York
|
+$6.37M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$33.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.12M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.52M |
| 4 |
BC
Broadfin Capital
New York
|
-$7.66M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$5.44M |
HRTX Hedge Fund Activity: Q2 2017 in Review
104 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2017, worth a combined $964M — down 10% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new HRTX positions and 11 closed out — a net gain of 5 holders — while 47 added to existing stakes and 25 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $81.7M. The largest seller was Invesco, cutting an estimated $33.6M.
- 104 institutional investors held Heron Therapeutics (HRTX) as of Q2 2017, up from 100 in Q1 2017.
- Funds reported $964M of Heron Therapeutics stock for Q2 2017, down 10% quarter-over-quarter.
- 16 funds opened new Heron Therapeutics positions in Q2 2017 and 11 closed out, a net change of +5 holders.
- The largest Heron Therapeutics buyer in Q2 2017 was Janus Henderson Group, an estimated $81.7M added.
- The largest Heron Therapeutics seller in Q2 2017 was Invesco, an estimated $33.6M sold.
Based on aggregated 13F filings for Q2 2017.